Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) insider Blake Aftab sold 6,968 shares of the stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $18.00, for a total transaction of $125,424.00. Following the transaction, the insider now owns 38,967 shares in the company, valued at $701,406. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Blake Aftab also recently made the following trade(s):
- On Monday, August 1st, Blake Aftab sold 6,968 shares of Adicet Bio stock. The shares were sold at an average price of $16.64, for a total transaction of $115,947.52.
- On Tuesday, July 5th, Blake Aftab sold 1,363 shares of Adicet Bio stock. The shares were sold at an average price of $14.50, for a total transaction of $19,763.50.
Adicet Bio Stock Up 2.7 %
Shares of ACET stock opened at $18.74 on Friday. The firm’s 50-day moving average is $14.64 and its two-hundred day moving average is $14.44. Adicet Bio, Inc. has a 12 month low of $6.25 and a 12 month high of $21.17.
Analyst Ratings Changes
ACET has been the subject of several recent analyst reports. TheStreet downgraded shares of Adicet Bio from a “c-” rating to a “d+” rating in a research note on Wednesday, June 1st. JMP Securities restated a “buy” rating and issued a $21.00 target price on shares of Adicet Bio in a research note on Tuesday, June 7th. Finally, StockNews.com downgraded shares of Adicet Bio from a “hold” rating to a “sell” rating in a research note on Thursday, July 28th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Adicet Bio has an average rating of “Moderate Buy” and an average target price of $29.29.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Adicet Bio by 69.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,672 shares of the company’s stock worth $33,000 after purchasing an additional 685 shares during the period. J. Goldman & Co LP raised its position in Adicet Bio by 4.7% during the 1st quarter. J. Goldman & Co LP now owns 19,650 shares of the company’s stock worth $392,000 after buying an additional 878 shares during the last quarter. American International Group Inc. raised its position in Adicet Bio by 15.1% during the 1st quarter. American International Group Inc. now owns 12,789 shares of the company’s stock worth $255,000 after buying an additional 1,675 shares during the last quarter. Amalgamated Bank purchased a new position in Adicet Bio during the 1st quarter worth $51,000. Finally, JPMorgan Chase & Co. raised its position in Adicet Bio by 18.1% during the 1st quarter. JPMorgan Chase & Co. now owns 16,766 shares of the company’s stock worth $335,000 after buying an additional 2,564 shares during the last quarter. Institutional investors and hedge funds own 76.21% of the company’s stock.
Adicet Bio Company Profile
Adicet Bio, Inc, a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients.
- Get a free copy of the StockNews.com research report on Adicet Bio (ACET)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.